Factor IX variants improve gene therapy efficacy for hemophilia B

Abstract excerpt

Intramuscular injection of adeno-associated viral (AAV) vector to skeletal muscle of humans with hemophilia B is safe, but higher doses are required to achieve therapeutic factor IX (F.IX) levels. The efficacy of this approach is hampered by the retention of F.IX in muscle extracellular spaces and by the limiting capacity of muscle to synthesize fully active F.IX at high expression rates. To overcome these...

Topics

Join the communities discussing this publication.

• CAR-T cell therapy research
• Viral Infectious Diseases and Gene Expression in Insects
• Virus-based gene therapy research